And LHX6EX(+12) isoform group was the predominant oncogenic subtype of LHX6 in cervical cancer, which could be a new biomarker and a potential precise therapeutic target for cervical cancer in the future. This evidence concerns the gene LHX6 and cervical carcinoma.